Ebola Outbreak Escalates Urgency and Spikes Visibility for Emerging Contender in Biothreat Detection -- PositiveID Corp. Investor Update by SmallCapTraders.com
4:01p ET August 7, 2014 (PR NewsWire) Print
PositiveID Corp. (OTCQB: PSID), with offices in Delray Beach, FL and Pleasanton, CA, is an emerging player in the biothreat detection market. The recent high visibility Ebola outbreak has created significant alarm among government officials as well as industry experts with a steady stream of media coverage flowing out over the last several days as the public follows the story closely. A number of industry experts and potential contenders in the market for diagnostic testing products have surfaced with various opinions and potential solutions with varying degrees of applicability to the near term problem at hand; preventing uncontrolled spread of Ebola (and other bio-threats) that could result in a pandemic or other major public health crisis.
PSID has a potentially game changing disruptive technology without any apparent current competition. Currently state of the art Ebola tests use polymerase chain reaction (PCR) a molecular diagnostic technology used to amplify a single or a few copies of a piece of DNA across several orders of magnitude. Expedited test results currently must be sent to a lab and take about 8 hours to turn around. PSID Firefly handheld technology may be able to produce valid test results on site eliminating the need to send samples to a lab and simultaneously reduce the total time for a result to 30 minutes. Reductions in testing time of that magnitude combined with eliminating the need to send samples to a lab would be truly revolutionary.
>>>>>>>>>>>>>>>>
July 17, 2014
PositiveID Receives New Order to Support M-BAND System for U.S. Government Contract
Order Increases the Value of Existing Department of Defense Contract; PositiveID Increases Revenue/Backlog Estimate to $3.5 Million; Reiterates Revenue Guidance of $4-10 Million Through the End of 2015
DELRAY BEACH, Fla., July 17, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has received a new order from a large government contractor for the continued testing and evaluation of PositiveID's M-BAND (Microfluidic Bioagent Autonomous Networked Detector) in support of an existing U.S. government contract. In keeping with contractual obligations the contractor and program have not been named. As a result of this new purchase order, the company has increased its 2014/2015 revenue and backlog (backlog added to revenue recognized) estimate from $3.3 million to $3.5 million, and is reiterating its revenue guidance of $4-10 million through the end of 2015 (2014 and 2015 combined).
"We view this latest purchase order as another validation of not only our technical capabilities, but also our ability to collaborate with large commercial and government partners, while continuing to execute our strategy," stated William J. Caragol, Chairman and CEO of PositiveID. "We are very pleased to continue the testing of our M-BAND units to protect our nation's warfighters and defenders."
IMHO ALL this applies even more now it being late October..... Look for news soon here folks !
News 
Market Data 
Discover 
